McGee Claire, Liebert Ann, Herkes Geoffrey, Bicknell Brian, Pang Vincent, McLachlan Craig S, Kiat Hosen
Faculty of Health Sciences, Torrens University, Sydney, NSW, Australia.
School of Medical Sciences, University of Sydney, Camperdown, NSW, Australia.
Front Neurosci. 2022 Aug 17;16:945796. doi: 10.3389/fnins.2022.945796. eCollection 2022.
Parkinson's disease (PD) is the second most common, progressive, and debilitating neurodegenerative disease associated with aging and the most common movement disorder. Photobiomodulation (PBM), the use of non-thermal light for therapeutic purposes using laser or light emitting diodes (LED) is an emerging non-invasive treatment for a diverse range of neurological conditions. The main objectives of this clinical trial are to investigate the feasibility, safety, tolerability, and efficacy of a novel transcranial LED helmet device (the "PDNeuro") in the alleviation of symptoms of PD.
This is a 24-week, two-arm, triple-blinded randomized placebo-controlled clinical trial of a novel transcranial "PDNeuro" LED Helmet, comparing an active helmet to a sham helmet device. In a survey, 40 PD participants with Hoehn and Yahr Stage I-III during ON periods will be enrolled and randomly assigned into two groups. Both groups will be monitored weekly for the safety and tolerability of the "PDNeuro" LED Helmet. Clinical signs and symptoms assessed will include mobility, fine motor skills and cognition, with data collected at baseline, 12 weeks, and 24 weeks. Assessment tools include the TUG, UPDRS, and MoCA all validated for use in PD patients. Patient's adherence to the device usage and participant drop out will be monitored weekly. At 12 weeks both placebo and treatment groups will crossover and placebo participants offered the treatment. The main indicator for clinical efficacy of the "PDneuro" Helmet is evidence of sustained improvements in motor and non-motor symptoms obtained from participant self-reported changes, carer reporting of changes and objective reassessment by the investigators. The outcomes will assist in a future larger randomized trial design.
[https://www.anzctr.org.au], identifier [12621001722886].
帕金森病(PD)是与衰老相关的第二常见、进行性且使人衰弱的神经退行性疾病,也是最常见的运动障碍。光生物调节(PBM)是利用激光或发光二极管(LED)发出的非热光进行治疗的方法,是一种新兴的针对多种神经系统疾病的非侵入性治疗手段。本临床试验的主要目的是研究一种新型经颅LED头盔装置(“PDNeuro”)在缓解帕金森病症状方面的可行性、安全性、耐受性和疗效。
这是一项为期24周的双臂、三盲随机安慰剂对照临床试验,研究新型经颅“PDNeuro”LED头盔,将有源头盔与假头盔装置进行比较。在一项调查中,将招募40名处于开期、Hoehn - Yahr分级为I - III级的帕金森病参与者,并随机分为两组。两组将每周监测“PDNeuro”LED头盔的安全性和耐受性。评估的临床体征和症状将包括运动能力、精细运动技能和认知能力,在基线、12周和24周收集数据。评估工具包括经验证可用于帕金森病患者的TUG、UPDRS和MoCA。将每周监测患者对设备使用的依从性和参与者退出情况。在12周时,安慰剂组和治疗组将交叉,为安慰剂组参与者提供治疗。“PDneuro”头盔临床疗效的主要指标是参与者自我报告的变化、护理人员报告的变化以及研究者进行的客观重新评估所显示的运动和非运动症状持续改善的证据。这些结果将有助于未来更大规模的随机试验设计。